Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiaPrecise intralymphatic Diamyd in at-risk HLA DR3-DQ2 youth
2024-513350-30-00Phase 2Completed
- Sponsor
- Diamyd Medical
- Start
- Jun 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Diamyd in diabetes mellitus type 1 (T1D), sponsored by Diamyd Medical. Primary endpoint: Feasibility and safety of intralymphatic Diamyd administration. Started Jun 2024; status: completed.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-513350-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513350-30-00.